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Extracts from termite-associated bacteria were evaluated for in vitro antiviral activity against bovine viral diarrhea virus (BVDV).
Two bacterial strains were identified as active, with percentages of inhibition (IP) equal to 98%. Both strains were subjected to
functional analysis via the addition of virus and extract at different time points in cell culture; the results showed that they were
effective as posttreatments. Moreover, we performed MTT colorimetric assays to identify the CC
50
, IC
50
, and SI values of these
strains, and strain CDPA27 was considered the most promising. In parallel, the isolates were identified as Streptomyces through
16S rRNA gene sequencing analysis. Specifically, CDPA27 was identified as S. chartreusis. The CDPA27 extract was fractionated on
a C18-E SPE cartridge, and the fractions were reevaluated. A 100% methanol fraction was identified to contain the compound(s)
responsible for antiviral activity, which had an SI of 262.41. GC-MS analysis showed that this activity was likely associated with the
compound(s) that had a peak retention time of 5min. Taken together, the results of the present study provide new information for
antiviral research using natural sources, demonstrate the antiviral potential of Streptomyces chartreusis compounds isolated from
termite mounds against BVDV, and lay the foundation for further studies on the treatment of HCV infection.
1. Introduction
Infections with bovine viral diarrhea virus (BVDV) lead to
significant economic losses for cattle producers worldwide.
This virus is associated with transient fever and diarrhea as
well as disorders that affect milk production [1]. BVDV is a
member of the Flaviviridae family and Pestivirus genus [2].
While there are differences among themembers of this genus,
BVDV shares similarities in replication cycle, biology, and
genetic organizationwith hepatitis C (HCV), amember of the
same family as BVDV but from the Hepacivirus genus [3].
Based on these similarities, BVDV is widely used as a
surrogate model for in vitro antiviral studies against HCV, as
HCV does not efficiently replicate in cell culture [4].
There are no available vaccines for the prevention of HCV
infection, and current therapy involves a combination of
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interferon-R (PEG-INF) and ribavirin (1-𝛽-D-ribofuranosyl-
1,2,4 triazole-3-carboxamide), a nucleoside analog [5, 6]. In
addition to its costliness, this treatment is only effective for
HCV genotype 1-infected patients and produces numerous
side effects, including psychiatric disorders, hemolytic ane-
mia, and changes in blood cell counts, leading to discontinua-
tion [5, 7]. Protease inhibitors (PI), including boceprevir and
telaprevir, have revolutionized the treatment of HCV geno-
type 1 infections; however, combination treatments using PIs
have been associated with adverse events, which also lead to
the early termination of therapy [8].
Thus, the development of a low-cost therapy with few
collateral side effects is a priority.
Natural products comprise substanceswith diverse chem-
ical structures, providing a substantial pool of potential new
drugs [9, 10].
In traditional medicine, termites and termite mounds
have been used to treat different diseases worldwide. The
termite is commonly used in northern Brazil and in indige-
nous communities in different parts of the world, such as
in the Pareci and Kadiwe´u communities, particularly for the
treatment of asthma and dermatological problems [11–13].
Additionally, the use of tea-crushed insects or inhalation
of incinerated termite soil has previously been reported in
cases of bronchitis, wounds, colds, flu, rheumatism, and other
conditions [12]. Recently, the termite has also been described
as a source of natural products with antibiotic and antifungal
activities [14].
Because of the significant difficulties in treating and
preventing HCV and the therapeutic potential of natural
compounds with antiviral activities, we analyzed the effects
of bacteria collected from different termite mounds against
BVDV.
2. Materials and Methods
2.1. Bacteria
2.1.1. Isolation and Maintenance of Microorganisms. Samples
of termite mounds were collected between October 2008 and
February 2009 from different municipalities in Bahia, Brazil,
includingMorro doChape´u (11∘33󸀠08󸀠󸀠S, 41∘09󸀠27󸀠󸀠W), Lafai-
ete Coutinho (13∘38󸀠11󸀠󸀠S, 40∘12󸀠43󸀠󸀠W), and Feira de San-
tana (12∘16󸀠23󸀠󸀠S, 38∘57󸀠19󸀠󸀠W). The samples were placed in
sterilized polyethylene bags and immediately transported to
the Laborato´rio de Pesquisa em Microbiologia (LAPEM) at
Universidade de Feira de Santana, Bahia, Brazil. A 10 g sample
of termitemoundwas suspended in 90mLof sterilewater and
manually homogenized for 2min. Aliquots of 100mL (10−1 at
10−5) were inoculated onto Petri dishes containing three dif-
ferent media: ISP2A (10.0 g soluble starch, 4.0 g yeast extract,
10.0 g malt extract, 4.0 g dextrose, and 20.0 g agar in 1000mL
distilled water; pH 7.0–7.2); CCA (10 g soluble starch, 0.3 g
KNO
3
, 2.0 g NaCl, 2.0 g K
2
PO
4
⋅3H
2
O, 2.0 g MgSO
4
, 0.02 g
CaCo
3
, 0.01 g FeSO
4
, and 20.0 g agar in 1000mL distilled
water; pH 7.0–7.2), and ISP3 (HIMEDIA). The culture media
were supplemented with cycloheximide (50mgmL−1) to
control fungal growth. All plates were incubated at 30∘C, and
the appearance of colonies for bacterial isolationwas assessed
daily. Pure cultures were obtained after serial transfer into the
same culture conditions as above for isolation. The isolates
were maintained at −80∘C in 20% glycerol until further use.
2.1.2. Identification of Bacteria through 16S rRNA Gene
Sequencing Analysis. After allowing the bacteria to grow
on agar plates, genomic DNA was extracted from the pure
cultures according to a protocol published by Van Soolingen
et al. [15]. The 16S ribosomal DNA gene fragments were
PCR-amplified using the primers p10f (5󸀠 GAG TTT GAT
CCT GGC TCA G 3󸀠) and 1525R (5󸀠 AAG GAG GTG CC
3 WTC CAR 3󸀠), which were homologous to conserved
regions of the bacterial 16S ribosomal RNA (rRNA) gene
[16]. Fifty-microliter reaction mixtures containing 50–100 ng
genomicDNA, 2UTaqDNApolymerase (Invitrogen), 1x Taq
buffer, 1.5mM MgCl
2
, 0.2mM dNTP mix (GE Healthcare),
and 0.4 𝜇M of each primer were used. The amplification
program included 1 cycle at 95∘C for 2min, 30 cycles at
94∘C for 1min, 55∘C for 1min, 72∘C for 3min, and a final
extension at 72∘C for 3min using an Eppendorf thermal
cycler. PCR amplification of the 16S rRNA gene fragments
was confirmed on a 1% agarose gel stained with SYBR
Safe (Invitrogen). The 16S rRNA gene fragments were fur-
ther purified using mini columns (GFX PCR DNA and
Gel Band Purification Kit, GE Healthcare) and sequenced
using an automated sequencer (ABI3500xL).The sequencing
reactions were performed using a BigDye Terminator v3.1
Sequencing Kit (Life Technologies). The primers used in
the sequencing reactions were 10f (5󸀠 GAG TTT GAT CCT
GGC TCA G 3󸀠), p765f (5󸀠 AGA TAC ATT CCT GGT
AG 3󸀠), p782r (5󸀠 ACC AGG GTA TCT AAT CCT GT 3󸀠),
1100R (5󸀠 GGC CTC AGG GTT GTT G 3󸀠), and 1525R
(5󸀠 AAG GAG GTG CC 3 WTC CAR 3󸀠). The obtained
sequences were processed using the Phred/Phrap/Linux
version of the CONSED program for the assembly of
contigs [17, 18]. The final obtained sequence was approx-
imately 1100 bp and was compared against sequences in
GenBank (http://www.ncbi.nlm.nih.gov/BLAST/) and Ribo-
somal Data Project II 9.0 (http://rdp.cme.msu.edu/index.jsp).
Sequences retrieved from the databases were aligned using
the CLUSTAL X program [19], and phylogenetic analyses
were conducted using the MEGA program, version 5 [20].
An evolutionary distance matrix was calculated using a
previously described model [21], and a phylogenetic tree
was constructed based on evolutionary distances using the
neighbor-joining method [22], with values calculated from
1000 bootstrap resamples [23].
2.2. Extracts
2.2.1. Crude Extracts. A total of 90 bacterial extracts
were obtained using liquid-liquid extraction [3]. Briefly, a
preinoculum of the isolates was cultured in 7mL of isolation
medium (Nutrient Broth, NB) and incubated at 30∘C at
120 rpm. After 48 h, the total volume was transferred to an
Erlenmeyer flask containing 50mL of the same medium
and maintained at the same temperature and rotation for
48 h. Subsequently, 50mL of the bacterial suspension was
transferred to a glass jar containing 500mL of the same
Evidence-Based Complementary and Alternative Medicine 3
medium andmaintained under the same conditions as above
for four weeks. Then, 500mL of P.A. grade ethyl acetate
was added, and the mixture was triturated in a blender
at high-speed rotation. After 24 h, the mixture was filtered
using a Buchner funnel containing a PTFE frit-layer of Celite
(diatomaceous earth), and the organic phase was recovered
in an Erlenmeyer flask using a separator funnel. Cell debris
and culture medium were retained in the aqueous phase, and
potentially biologically active metabolites were recovered in
the organic phase. The organic phase was transferred to a
round-bottom flask.
The organic solvent was removed using a Buchi Rotava-
por R-215 with vacuum at 37∘C until the solvent was com-
pletely dry. Subsequently, the extracts were suspended in
ethyl acetate and water and transferred to new glass tubes
using Pasteur pipettes. These tubes were placed in a Savant
vacuum centrifuge (model 210A SpeedVac Plus SC) for evap-
oration, and the samples were freeze-dried. After complete
drying, the extracts were dissolved in 10% dimethylsulfoxide
(DMSO) andmaintained at−4∘Cuntil further use in antiviral
activity assays.
2.2.2. Fractionation. The extract presenting the best results,
that is, the highest inhibition percentage (IP) and highest
selectivity index (SI), was selected for fractionation to identify
the potential active compound(s) responsible for its antiviral
activity.
The extracts were fractionated using Phenomenex Strata
Reversed Phase C18-E SPE cartridges containing 500mg of
adsorbent (sorbent lot number S201-141). Each cartridge was
preconditioned with 100% methanol (3mL) and equilibrated
with 100% water (3mL). Subsequently, each sample was
loaded onto the top of the cartridge using a Pasteur pipette
at 30mg/mL sorbent mass, followed by elution with 3mL of
a water/methanol mixture in a gradient starting from the first
fraction. The following fractions were sequentially collected:
(1) water/methanol (95/05), (2) water/methanol (90/10), (3)
water/methanol (80/20), (4) water/methanol (70 : 30), and (5)
water/methanol (50 : 50). At the end of the procedure, the
cartridgewas rinsedwith 100%methanol to remove unbound
material, which was designated fraction 6.The fractions were
stored at 8∘C until antiviral activity analysis using GC-MS
coupling.
2.3. Antiviral Activity Assay
2.3.1. Virus and Cell Lines. The Madin-Darby bovine kidney
(MDBK) cell line was used for inoculation with the BVDV
strain Cepa Singer. The virus was propagated in monolayer
culture using minimal essential medium (MEM) containing
Earle’s salts. The MDBK cells were supplemented with 10%
equine serum (ES). Medium without serum was used when
the virus was incubated with the MDBK cells.
2.3.2. MTT Assay. The MTT assay is a sensitive in vitro
assay for the measurement of cell proliferation or cell
viability reduction. To perform the assay, the MDBK
cells were cultured in 96-well tissue culture plates. The
tetrazolium compound MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide) was then added to the
wells, and the plates were further incubated. MTT is reduced
to insoluble purple formazan crystals in metabolically active
cells. An aliquot of 150𝜇L DMSO was subsequently added
to each well to solubilize the crystals, and the absorbance
was read at 540 nm using a spectrophotometer [24, 25].
The data were analyzed after plotting cell number versus
absorbance to quantitate changes in cell proliferation. The
rate of tetrazolium reduction is proportional to the rate of
cell proliferation and indirectly indicates reductions in cell
viability in response to virus infection.
2.3.3. Titration of the Virus. Cells were seeded onto 96-well
culture plates at a density of 105 cells/mL and subsequently
incubated at 37∘C for 24 h in a humidified atmosphere
containing CO
2
. Tenfold serial dilutions of the virus stocks
were prepared in culture medium, and the cells were infected
with the diluted virus. After additional incubation (1-2 days),
the cytopathic effect was recorded. The 50% tissue-culture
infective dose (TCID
50
) per mL was calculated as previously
described [26].
2.3.4. Antiviral Activity. Antiviral activity was determined
based on inhibition of the cytopathic effect. All experiments
were performed in quadruplicate. Briefly, to evaluate inhi-
bition, cells were seeded onto 96-well culture plates. After
incubation for 24 h, the medium was replaced with 100 𝜇L of
MEM(E) containing 50 𝜇g/mL bacterial extract, and 50 𝜇L of
100 TCID
50
/50 𝜇L of virus was added and incubated for 72 h.
The controls comprised untreated infected cells (virus at 100
TCID
50
/50 𝜇L), treated noninfected cells (extract control),
and untreated noninfected cells. The cytopathic effect was
observed, and the extracts possessing antiviral activity were
identified. Antiviral activity was determined using an MTT
assay to quantify the protection conferred by a cell extract
against the virus. The protection percentage was calculated
using the following formula [27]: (absorbance of treated cells
− absorbance of the control virus)/(absorbance of the cellular
control − absorbance of the control virus) × 100.The antiviral
activity was initially evaluated with a single dose of 50𝜇g/mL
against 100 TCID
50
/mL of virus. Extracts with activities
higher than 90% were considered promising. However, only
extracts with IPs higher than 98%were considered active and
selected for further examination.
To confirm antiviral activity, a concentration-response
curve using different concentrations of extract in the presence
of 100 TCID
50
/mL of virus was constructed using the MTT
assay to determine the 50% inhibitory concentration (IC
50
).
The IC
50
was calculated from the concentration-response
curve using linear regression analysis. The results were
obtained from triplicate assays using at least five extract
concentrations. The 50% cytotoxicity concentration (CC
50
)
was calculated as [(𝐴−𝐵)/𝐴]×100, where𝐴 and 𝐵 represent
the OD
540
values of untreated and treated cells, respectively.
The percentage protection was calculated as [(𝐴 − 𝐵) ×
100/(𝐶 − 𝐵)], where 𝐴, 𝐵, and 𝐶 indicate the absorbance
values of the extract, virus, and control cells, respectively.
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Figure 1: Experimental design employed in this study.
Each IC
50
value was defined as the effective concentration
necessary to reduce the absorbance of infected cells by
50% compared with the cell and virus controls. The CC
50
and IC
50
values represented the averages of three assays
using five concentrations within the inhibitory ranges of the
compounds. The therapeutic index (i.e., SI) was defined as
CC
50
/IC
50
.
2.3.5. Viral Infection Cycle Staging. Cells and viruses were
incubated with active extracts at different stages during the
viral infection cycle to determine the antiviral mechanism.
The cells were pretreated with bacterial samples prior to
viral infection (pretreatment); viruses were incubated with
the bacterial samples prior to infecting the cells (virucidal
action); or the cells were infected and incubated together with
the virus before the addition of the bacterial samples (post-
treatment). The samples were used at the maximum non-
cytotoxic concentration. The antiviral activity was expressed
as the titer (TCID
50
/𝜇L) and IP, as previously described by
Koseki et al. [28]. The IP was calculated using the formula
(IP) = (1 − 𝑇/𝐶) × 100, where 𝑇 is the antilog of the extract-
treated viral titers and 𝐶 is the antilog of the control (without
extract) viral titers. An IP greater than or equal to 97% was
considered positive.
2.4. GC-MS Analysis. The crude extracts and active fractions
were analyzed usingGC-MS.The analyseswere performedon
an Agilent 6890N gas chromatograph (Palo Alto, CA, USA)
interfaced with an Agilent 5975 Mass Selective Detector and
an HP 7683B automatic injector, fitted with a fused methyl
silicon HP-5MS column (30m × 0.25mm i.d., 0.25𝜇m film
thickness) containing 5% phenyl and 95% methylsiloxane.
Helium was used as a carrier gas at a flow rate of 1.0mL/min.
The oven temperature was maintained at 150∘C for 2min
and subsequently increased to 240∘C at a rate of 5∘C/min,
followed by an increase to 300∘C at a rate of 10∘C/min. It
was thenmaintained constant for at least 34min.The injector
temperature was maintained at 280∘C, and the split ratio
was adjusted to 1 : 50. Mass spectral (MS) data were obtained
under the following conditions: ionization potential 70 eV,
50–480 amu scan range, 2 sec scan time, detector temperature
300∘C, and solvent delay 3min.The samples were solubilized
in ethyl acetate at a concentration of 20mg/mL and injected
into a gas chromatograph column. The constituents of the
extracts were identified by comparing the mass spectral data
and retention times with corresponding data obtained from
the literature and the NIST 2005 computerizedMS databank,
using 90% as the minimum identification criterion.
2.5. Statistical Analysis. The results are expressed as the
means ± SEM. Significantly different effects of the tested
extracts on the inhibition of virus replication were compared
with the control group using Student’s 𝑡-test, with significance
considered at 𝑝 ≤ 0.05.
3. Results
A total of 90 extracts from different bacterial species pre-
viously collected from termites in three regions of Bahia
in northeastern Brazil (Lafaiete Coutinho, Feira de Santana,
and Morro do Chape´u) were examined. The culture medium
used for bacterial growth (NB medium, Oxoid) was used as
a control to ensure that there was no interference with the
tested compounds produced from the bacteria.
Among the extracts analyzed, 11 samples showed IP values
against BVDV that were greater than or equal to 90%. A
flowchart of the experiments is shown in Figure 1.
The extracts listed in Figure 2 showed promising results.
The active extracts with IP values greater than 98% included
CDPA27 and MC51. The stage of the viral replication cycle
duringwhich the extracts exerted their actionswas identified,
and the SI values (i.e., CC
50
/IC
50
) of the compounds, which
indicate their potential to inhibit viral replication without
inducing cell damage, were calculated.Thus, a direct relation-
ship could be established between SI value and the potential
of an extract as an antiviral compound. To identify the stage of
the viral replication cycle during which an active compound
operated, three different treatments were administered: (1)
the cells were infected with virus for 1 h, followed by the
addition of extract to evaluate the viral replication phase
(posttreatment); (2) the virus was pretreated with extract
prior to infecting the cells (virus inactivation); and (3) extract
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Table 1: Potential mechanism, selectivity index (SI), 50% cytotox-
icity concentration (CC
50
), and concentration inhibiting 50% viral
replication (IC
50
) of the active extracts.
Virus Extract CC
50
IC
50
SI Mechanism of action
BVDV CDPA27 409.3 139.8 3.50 Posttreatment
MC51 32.31 16.99 1.90 Posttreatment
BVDV: bovine viral diarrhea virus; CC50: concentration inhibiting 50% cell
growth; IC50: concentration inhibiting 50% viral replication.
Table 2
Active fraction CC
50
IC
50
SI
Fraction 6 (100%MeOH) 227.8 0.8681 262.4121
CC50: concentration inhibiting 50% cell growth; IC50: concentration inhibit-
ing 50% viral replication; SI: selectivity index.
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Figure 2: Percentages of inhibition (IP) of the promising extracts.
was added to the cells prior to viral infection to evaluate
viral adsorption effects (pretreatment). The SI results and
identified mechanisms of action are detailed in Table 1.
In addition, we conducted a phylogenetic analysis of
the active bacterial compounds based on the ribosomal
operon to identify these microorganisms. This technique is
useful for the identification of many bacterial species. In the
present study, the strain with the highest degree of activity
against BVDV, strain CPDA27, was identified as Streptomyces
chartreusis. Strain MC51 was also identified as a member
of the Streptomyces genus; however, it was not possible to
identify the species of this strain. The phylogenetic tree that
was constructed using the above data is presented in Figure 3.
According to the above results, the S. chartreusis extract
had the best IP and SI values. Thus, this strain was selected
for further analysis via fractionation using a C18-E cartridge,
and the fractions were reevaluated. The results are shown in
Figure 4 and Table 2. Analyzing the IP values of the fractions
revealed that fraction 6 (100% methanol) contained the
compounds responsible for the observed antiviral activity
(Figure 4). The SI of the active fraction, highlighted in
Table 2, was 262.41, supporting the use of this sample in future
assays.
To identify the compounds responsible for the antiviral
activity described in the present study, the crude bacterial
extract, the active fraction, and a control sample of the culture
mediumwithout bacteria were analyzed using GC-MS. It was
possible to identify the compounds present in both the crude
extract and the active fraction and those that were not present
in the control sample, suggesting that these compounds were
solely derived from S. chartreusis fermentation (Figure 5).
Compared with the control, peaks were observed at
certain retention times that corresponded to the compounds
derived exclusively from bacterial fermentation and that
were potentially responsible for antiviral activity. The chro-
matographic analysis of the CDPA27 extract revealed that
the compounds produced by the bacteria appeared at the
beginning of the chromatogram. These same compounds
were also identified in active fraction 6 (100% methanol).
Thus, these results suggest that the antiviral activity
against BVDV described in the present study is associated
with the compounds that produced peaks with 5min reten-
tion times.
Although the compounds identified in the present study
were thoroughly analyzed, it was not possible to detect
similarities between the compounds represented by each
peak on themass fragmentogramand the compounds present
in the utilized databases.
4. Discussion
Approximately 3% of the world’s population (170 million
people) is afflicted with chronic HCV infections, which
pose a risk for the development of cirrhosis, hepatocellular
carcinoma, and liver failure [29–31].
The search for new therapeutic agents to control virus
infection is one of the highest priorities in virological research
[32], and an increasing number of recent studies have focused
on utilizing natural sources to solve medical challenges [33].
Despite the popular use of termites and termite mounds
in populations from different regions of the world [12], the
antifungal [34] and antibiotic properties [35] of these treat-
ments have only recently been examined. In the present study,
we examined the potential antiviral activities of termite-
associated bacteria.
Amajor component of themicrobiota of several species of
termites is Actinobacteria, which are present in the intestines
and on the body surfaces of these insects [36, 37]. Acti-
nobacteria, also known as actinomycetes, are Gram-positive
bacteria that produce a variety of secondary metabolites
considered to be promising candidates for active natural
compounds [35].
In the extracts tested in the current study, the strains
CDPA27 and MC51 were the most promising, and phy-
logenetic analysis identified both strains as Streptomyces.
This genus has also consistently been described to produce
secondary metabolites, such as those obtained from Strepto-
myces sp. K15, with significant antimicrobial activities against
Botrytis cinerea [38]. Additionally, other Streptomyces species,
such as S. mutabilis, which was isolated from soil samples
in Saudi Arabia, exhibit promising antituberculous activity
[39], and Raveh et al. [40] reported the antiviral activity of
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Figure 3: Phylogenetic tree based on the analyses of 16S ribosomal RNA gene sequences of Actinobacteria (Kimura 2-parameter model,
neighbor-joining algorithm with 1000 bootstrap resamples). The sequence of the 16S ribosomal RNA gene from Gordonia terraeT (X79286)
was used as an outgroup.
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Figure 4: Percentage of inhibition (IP), selectivity index (SI), concentration inhibiting 50% cell growth (CC
50
), and concentration inhibiting
50% viral replication (IC
50
) of the active fraction (see Table 2).
a compound isolated from marine sediments obtained from
S. kaviengensis against western equine encephalitis virus that
inhibits the mitochondrial electron transport chain.
The most promising extract in the current study was
derived from the fermentation of S. chartreusis. Leach et
al. [41] first described this species as being responsible for
the production of chartreusin, a compound with antibiotic
properties againstmanyGram-positive species, such asBacil-
lus subtilis and Brucella bronchiseptica, and Gram-negative
species, such as Salmonella typhosa, Escherichia coli, and
Proteus vulgaris; chartreusin has also shown activity against
mycobacteria. In 1958, Miyakawa et al. [42] evaluated the
antiviral activities of several antibiotics against influenza A
(strain RP
8
) and further confirmed the significant activity
of this compound. Moreover, chartreusin has also been
described to possess antitumor activity against murine L1210
and P388 leukemias and B16 melanoma [43]. Furthermore,
Aoyama et al. [44] described a minor component of crude
chartreusin (3-demethylchartreusin) as a new antitumor
antibiotic.
In the present study, the results of antiviral activity assays
revealed thatCDPA27 affects viral replication; that is, it acts as
a posttreatment.This result is consistent with the antitumoral
mechanism of chartreusin, which binds to DNA and inhibits
the activity of topoisomerase II, interfering with subsequent
stages of replication [45]. However, GC-MS analysis did not
detect overlaps between database results and the compounds
of interest that were present in the fractions and crude extract
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Figure 5: Chromatographic analyses of the control, CDPA27 (crude extract), and fraction 6 (100% MeOH).
of this bacterial strain. Chartreusin is described in the utilized
database, thereby eliminating the possibility that the antiviral
activity described in the present study can be attributed to this
compound (Figure 4, Table 2).
In conclusion, the data obtained in the present study were
used to identify a bacterial species isolated from termites,
that is, a promising producer of secondary metabolites with
antiviral activities against BVDV, which serves as a surrogate
model of HCV. From this study, it can be concluded that Acti-
nomycetes collected and isolated from termite mounds can
be used as sources of pharmacologically active compounds
that may be used for the synthesis of new drugs to treat
patients with hepatitis C. However, further studies are needed
to identify the active compound(s) in the extracts that were
evaluated in this study.
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